Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors
We found that 17% of PT incidence correlated with relatively high bone metastatic burden and spleen length. Physicians should be vigilant in the event of a significant drop in platelet count after the first cycle of PRRT.
Authors
- Thibaut Reichert
- Sandrine Oziel-Taïeb
- Daniel Ouk
- Jemima Maniry-Quellier
- Romain Ferrara
- Nathalie Charrier
- Patricia Niccoli
- Christophe Zemmour (ORCID: https://orcid.org/0000-0002-8483-6117)
- I. Brenot-Rossi
Institutions
- Institut Paoli-Calmettes (FR)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3389/fendo.2025.1568243
- Citations
- 2
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.71